Overview

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Lenvatinib